Brimonidine/timolol combination solution is FDA-approved for glaucoma.
Allergan has received an agency nod for its combination ophthalmic solution Combigan. The FDA approved the new product, which contains both brimonidine tartrate and timolol maleate, for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. During clinical studies, the alpha receptor agonist/beta receptor inhibitor combination provided additional IOP lowering beyond that of either brimonidine or timolol administered alone. According to Allergan, Combigan will be available in the fourth quarter of 2007.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.